



**Contact:**

Risa Goldman Burgess or Ted Smith  
Schwartz Communications, Inc.  
781-684-0770  
[verdezyne@schwartz-pr.com](mailto:verdezyne@schwartz-pr.com)

**CODA GENOMICS, INC. CHANGES COMPANY NAME TO VERDEZYNE**

**LAGUNA HILLS, Calif.— November 11, 2008** – CODA Genomics today announced that the company will begin doing business under the name Verdezyne, Inc., effective immediately. The company’s new Web site is [www.verdezyne.com](http://www.verdezyne.com).

Verdezyne employs its biology expertise and proprietary advanced computational algorithms to design and synthesize novel, high-diversity gene libraries for engineering proteins, metabolic pathways, and microorganisms. The company creates and harnesses this unique biological diversity to optimize commercial fermentation processes used to manufacture platform chemicals and biofuels. The new name better conveys the company’s focus on these key market segments.

“This is a very exciting time for our company. We have a highly experienced management team in place, a solid business plan that includes significant internal R&D efforts and strategic relationships with key industrial partners,” said E. William Radany, Ph.D., President and Chief Executive Officer, Verdezyne. “Our new name and focus solidifies our commitment to the burgeoning industrial biotechnology marketplace.”

This news follows the recent announcement of Dr. Stephen Picataggio’s appointment to Chief Scientific Officer. Under Dr. Picataggio’s leadership, the company is planning to expand the scientific team to support the new R&D growth initiatives. “I’m convinced Verdezyne’s technology has tremendous potential for metabolic pathway engineering in the industrial biotechnology sector, and I’m delighted to join their management team to help establish a scientific roadmap and commercialization strategy to improve the commercial production of platform chemicals and biofuels,” said Dr. Picataggio.

Dr. Picataggio joins the executive management team of E. William Radany, Ph.D., President and Chief Executive Officer, Steve Jackson, Chief Financial Officer, Nancy Oleski, Ph.D., J.D., Senior Vice President of Intellectual Property and General Counsel, and Alan Carter, Senior Vice President of Sales and Marketing.

**About Verdezyne**

Founded in 2005, Verdezyne, formerly known as CODA Genomics, is a privately-held company that integrates its proprietary core technologies to direct the evolution of novel metabolic pathways for cost effective commercial production of biofuels and platform chemicals. Investors in Verdezyne include OVP Venture Partners, Monitor Ventures, Tech Coast Angels and Life Science Angels. For more information on Verdezyne, visit [www.verdezyne.com](http://www.verdezyne.com).

###